核酸療法市場規模、佔有率和成長分析（按產品、適應症、最終用戶和地區分類）—2026-2033年產業預測

全球核酸療法市場預計到 2024 年將達到 67 億美元，到 2025 年將達到 76.1 億美元，到 2033 年將達到 211.2 億美元，預測期（2026-2033 年）的複合年成長率為 13.6%。

受新型治療方法進展和核准數量不斷增加的推動，全球核酸療法市場正經歷強勁成長。核酸（包括DNA和RNA）在細胞內訊號傳導中發揮至關重要的作用，並且是治療多種慢性疾病（包括癌症、糖尿病、癲癇、結核病和愛滋病）的關鍵手段。由於療效的提升和創新藥物研發策略的出現，製藥和生物製藥產業正受到廣泛關注。隨著醫療機構積極採用這些強效治療方法，對核酸治療方法的需求持續成長，使該市場成為現代醫學和慢性病管理發展的關鍵參與者。這種快速成長展現了核酸療法廣闊的前景。

全球核酸療法市場促進因素

全球核酸療法市場受到分子技術進步和體學研究持續探索的顯著影響，促使許多公司加強投資。該市場競爭異常激烈，透過收購、合作和聯合研究等多元化商務策略獲取市場佔有率是重要的收入來源。例如，製藥公司之間的策略聯盟致力於發現、開發和商業化創新RNA治療方法，以滿足疫苗、感染疾病和腫瘤治療領域的需求。此類合作對於促進創新和推動這一充滿活力的領域的成長至關重要。

限制全球核酸療法市場的因素

全球核酸療法市場面臨的關鍵挑戰之一是如何將這些療法有效地遞送至目標細胞。成功與否取決於能否將療法精準遞送至目標組織和細胞，並最大限度地減少潛在的脫靶效應。遞送過程的複雜性對致力於最佳化核酸療法療效和安全性的研究人員和開發人員構成了重大障礙。因此，開發創新的遞送機制和策略仍然是業界亟待解決的問題，影響這些治療方法的整體發展和廣泛應用。

全球核酸治療藥物市場趨勢

全球核酸療法市場呈現強勁的上升趨勢，這主要得益於醫療服務和研究舉措投資的持續成長。資本流入的激增主要是由於遺傳性疾病和慢性病的日益普遍，促使治療領域亟需創新。核酸技術的進步，例如基於RNA的治療方法和基因編輯，正日益受到關注，因為它們與針對特定遺傳疾病的個人化醫療方法相契合。隨著醫療機構的發展和能力的提升，對核酸療法的需求預計將會增加，從而拓展治療選擇，並改善全球患者的治療效果。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 二手資料和一手資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2025）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 案例研究分析

全球核酸療法市場規模（按產品和複合年成長率分類）（2026-2033 年）

• 反義寡核苷酸（ASO）
• RNA干擾（RNAi）
• RNA適體

全球核酸療法市場規模（按適應症和複合年成長率分類）（2026-2033 年）

• 自體免疫疾病
• 感染疾病
• 遺傳性疾病
• 癌症
• 其他

全球核酸療法市場規模（依最終用戶分類）及複合年成長率（2026-2033 年）

• 醫院
• 診所
• 其他

全球核酸療法市場規模及複合年成長率（2026-2033）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2025 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 依業務板塊進行公司股票分析
  • 2023-2025年營收年比比較

主要企業簡介

• Wave Life Science Ltd.（Singapore）
• Imugene（Australia）
• Aileron Therapeutics Inc.（US）
• BioNTech SE（Germany）
• Protagonist Therapeutics Inc.（US）
• Replicate Bioscience Inc.（US）
• Eli Lilly and Company（US）
• Copernicus Therapeutics Inc.（US）
• Invio Pharmaceuticals Inc.（US）
• Benitec Biopharma（Australia）
• Alnylam Pharmaceuticals（US）
• Zydus Cadila（India）
• Excision BioTherapeutics（US）
• Pfizer Inc.（US）
• Rhythm Pharmaceuticals Inc.（US）
• Axcella Health Inc.（US）

結論與建議

Global Nucleic Acid Therapeutics Market size was valued at USD 6.7 Billion in 2024 and is poised to grow from USD 7.61 Billion in 2025 to USD 21.12 Billion by 2033, growing at a CAGR of 13.6% during the forecast period (2026-2033).

The global nucleic acid therapeutics market is experiencing robust growth, driven by advancements in novel therapies and increased approvals. Nucleic acids, including DNA and RNA, play a crucial role in cellular information transfer and are pivotal in treating various chronic diseases such as cancer, diabetes, epilepsy, tuberculosis, and AIDS. The sector is gaining traction due to enhanced therapeutic efficacy and innovative drug development strategies within the pharmaceutical and biopharmaceutical industries. As healthcare organizations increasingly embrace these potent therapies, the demand for nucleic acid-based treatments continues to rise, positioning this market as a key player in the evolution of modern medicine and chronic disease management. This surge reflects a promising future for nucleic acid therapeutics.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Nucleic Acid Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Nucleic Acid Therapeutics Market Segments Analysis

Global Nucleic Acid Therapeutics Market is segmented by Product, Indication, End-user and region. Based on Product, the market is segmented into Anti-Sense Oligonucleotides (ASO), RNA Interference (RNAi) and RNA Aptamers. Based on Indication, the market is segmented into Autoimmune Disorders, Infectious Diseases, Genetic Disorders, Cancer and Others. Based on End-user, the market is segmented into Hospitals, Physicians' Offices and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Nucleic Acid Therapeutics Market

The Global Nucleic Acid Therapeutics market is significantly influenced by advancements in molecular technologies and the continuous exploration of omics, prompting substantial investment from various companies. This market is characterized by intense competition, where gaining market share is achieved through diverse business strategies, including acquisitions, partnerships, and collaborations that serve as critical revenue channels. For instance, strategic alliances between pharmaceutical firms focus on discovering, developing, and commercializing innovative RNA-based therapies aimed at addressing needs in vaccines, infectious diseases, and oncology. Such collaborative efforts are essential for fostering innovation and driving growth within this dynamic sector.

Restraints in the Global Nucleic Acid Therapeutics Market

One significant challenge facing the Global Nucleic Acid Therapeutics market is the effective delivery of these therapies to designated target cells. Achieving successful delivery is crucial, as it requires the therapeutic agents to accurately reach the intended tissue or cells while minimizing potential off-target effects. This complexity in the delivery process poses a major obstacle for researchers and developers aiming to optimize the efficacy and safety of nucleic acid-based treatments. The need for innovative delivery mechanisms and strategies continues to be a pressing concern within the industry, impacting the overall advancement and adoption of these therapeutic modalities.

Market Trends of the Global Nucleic Acid Therapeutics Market

The Global Nucleic Acid Therapeutics market is witnessing a robust upward trend, driven by heightened investments in healthcare services and research initiatives. This surge in funding is largely attributable to the rising prevalence of genetic disorders and chronic diseases, prompting urgent innovations within therapeutic landscapes. Advances in nucleic acid technologies, such as RNA-based therapies and gene editing, are gaining traction as they align with personalized medicine approaches aimed at targeting specific genetic conditions. As healthcare facilities evolve and expand their capabilities, the demand for nucleic acid therapeutics is anticipated to grow, leading to enhanced treatment options and improved patient outcomes globally.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Case Study Analysis

Global Nucleic Acid Therapeutics Market Size by Product & CAGR (2026-2033)

• Market Overview
• Anti-Sense Oligonucleotides (ASO)
• RNA Interference (RNAi)
• RNA Aptamers

Global Nucleic Acid Therapeutics Market Size by Indication & CAGR (2026-2033)

• Market Overview
• Autoimmune Disorders
• Infectious Diseases
• Genetic Disorders
• Cancer
• Others

Global Nucleic Acid Therapeutics Market Size by End-user & CAGR (2026-2033)

• Market Overview
• Hospitals
• Physicians' Offices
• Others

Global Nucleic Acid Therapeutics Market Size & CAGR (2026-2033)

• North America (Product, Indication, End-user)
  • US
  • Canada
• Europe (Product, Indication, End-user)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product, Indication, End-user)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product, Indication, End-user)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Indication, End-user)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Wave Life Science Ltd. (Singapore)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Imugene (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aileron Therapeutics Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioNTech SE (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Protagonist Therapeutics Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Replicate Bioscience Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Copernicus Therapeutics Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Invio Pharmaceuticals Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Benitec Biopharma (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alnylam Pharmaceuticals (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Cadila (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Excision BioTherapeutics (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Rhythm Pharmaceuticals Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Axcella Health Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations